Blog

Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax

Photo from Jorge Cortes/X

Aug 18, 2024, 15:03

Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax

Jorge Cortes, Director of the Georgia Cancer Center, shared on X about recent paper by him as first author titled “Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)” published on Taylor and Francis Online.

Authors: Jorge Cortes, Brian A. Jonas, Gary Schiller, Alice Mims, Gail J. Roboz, Andrew H. Wei, Pau Montesinos, P. Brent Ferrell, Karen WL. Yee, Pierre Fenaux, Anthony Schwarer and Justin M. Watts

“Published the experience with olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax. Small series but providing useful information for a common scenario in the clinic.”

Source: Jorge Cortes/X

Alice Mims Andrew H. Wei Anthony Schwarer Anthony Schwarer and Justin M. Watts Brian A. Jonas cancer Gail J. Roboz Gary Schiller Jorge Cortes Justin M. Watts Karen WL. Yee Olutasidenib OncoDaily Oncology P. Brent Ferrell Pau Montesinos Pierre Fenaux Taylor and Francis Online venetoclax

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage